Cargando…

Apatinib versus sorafenib in patients with advanced hepatocellular carcinoma: a preliminary study

BACKGROUND: Apatinib, a selective inhibitor of vascular endothelial growth factor receptor 2 (VEGFR 2), has exhibited modest antitumor efficacy in hepatocellular carcinoma (HCC). We aimed to evaluate the effectiveness and tolerability of apatinib versus sorafenib in patients with advanced HCC. METHO...

Descripción completa

Detalles Bibliográficos
Autores principales:	He, Wei, Liao, Leen, Hu, Dandan, Li, Binkui, Wang, Chenwei, Qiu, Jiliang, Liao, Yadi, Liu, Wenwu, Yang, Zhiwen, Zhang, Yuanping, Yuan, Yichuan, Li, Kai, Yuan, Yunfei, Zheng, Yun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2020
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7475472/ https://www.ncbi.nlm.nih.gov/pubmed/32953800 http://dx.doi.org/10.21037/atm-20-5298

Ejemplares similares

Microwave ablation versus resection for hepatocellular carcinoma within the Milan criteria: a propensity-score analysis
por: Liu, Wenwu, et al.
Publicado: (2019)

Dysregulated Sp1/miR-130b-3p/HOXA5 axis contributes to tumor angiogenesis and progression of hepatocellular carcinoma
por: Liao, Yadi, et al.
Publicado: (2020)

Resection vs Ablation for Multifocal Hepatocellular Carcinomas meeting the Barcelona-Clinic Liver Cancer A Classification: A Propensity Score Matching Study
por: Liu, Wenwu, et al.
Publicado: (2019)

Elafin promotes tumour metastasis and attenuates the anti-metastatic effects of erlotinib via binding to EGFR in hepatocellular carcinoma
por: Wang, Chenwei, et al.
Publicado: (2021)

Correction to: Elafin promotes tumour metastasis and attenuates the anti-metastatic effects of erlotinib via binding to EGFR in hepatocellular carcinoma
por: Wang, Chenwei, et al.
Publicado: (2022)

S100A9 Derived from Chemoembolization‐Induced Hypoxia Governs Mitochondrial Function in Hepatocellular Carcinoma Progression
por: Zhong, Chengrui, et al.
Publicado: (2022)

Transarterial chemoembolization (TACE) combined with apatinib versus TACE combined with sorafenib in advanced hepatocellular carcinoma patients: a multicenter retrospective study
por: Qiu, Zhiyu, et al.
Publicado: (2021)

NXN suppresses metastasis of hepatocellular carcinoma by promoting degradation of Snail through binding to DUB3
por: Zhang, Yuanping, et al.
Publicado: (2022)

SNRPC promotes hepatocellular carcinoma cell motility by inducing epithelial‐mesenchymal transition
por: Zhang, Yuanping, et al.
Publicado: (2021)

Long- versus short-interval follow-up after resection of hepatocellular carcinoma: a retrospective cohort study
por: He, Wei, et al.
Publicado: (2018)

PRMT3-mediated arginine methylation of IGF2BP1 promotes oxaliplatin resistance in liver cancer
por: Shi, Yunxing, et al.
Publicado: (2023)

TACE-HAIC combined with targeted therapy and immunotherapy versus TACE alone for hepatocellular carcinoma with portal vein tumour thrombus: a propensity score matching study
por: Yuan, Yichuan, et al.
Publicado: (2023)

A novel NHEJ gene signature based model for risk stratification and prognosis prediction in hepatocellular carcinoma
por: Lin, Zhu, et al.
Publicado: (2023)

Impact of follow-up interval on patients with hepatocellular carcinoma after curative ablation
por: Liu, Wenwu, et al.
Publicado: (2018)

Conversion to Resectability Using Transarterial Chemoembolization Combined With Hepatic Arterial Infusion Chemotherapy for Initially Unresectable Hepatocellular Carcinoma
por: Li, Binkui, et al.
Publicado: (2021)

Resection versus Resection with Preoperative Transcatheter Arterial Chemoembolization for Resectable Hepatocellular Carcinoma Recurrence
por: Tao, Qiang, et al.
Publicado: (2018)

The role of clinically significant portal hypertension in hepatic resection for hepatocellular carcinoma patients: a propensity score matching analysis
por: He, Wei, et al.
Publicado: (2015)

Mutual Regulation of MiR-199a-5p and HIF-1α Modulates the Warburg Effect in Hepatocellular Carcinoma
por: Li, Binkui, et al.
Publicado: (2017)

Identification of MACC1 as a novel prognostic marker in hepatocellular carcinoma
por: Qiu, Jiliang, et al.
Publicado: (2011)

The Efficacy of Transarterial Chemoembolization plus Apatinib or Sorafenib in the Treatment of Advanced Hepatocellular Carcinoma
por: Chen, Lei, et al.
Publicado: (2021)

Efficacy and safety of sorafenib versus apatinib in the treatment of intermediate and advanced hepatocellular carcinoma: a comparative retrospective study
por: Wang, Yizhuo, et al.
Publicado: (2018)

Dysregulation of PLOD2 Promotes Tumor Metastasis and Invasion in Hepatocellular Carcinoma
por: Li, Keren, et al.
Publicado: (2023)

METTL9-SLC7A11 axis promotes hepatocellular carcinoma progression through ferroptosis inhibition
por: Bi, Fangfang, et al.
Publicado: (2023)

The effect of apatinib in the treatment of sorafenib resistant metastatic hepatocellular carcinoma: A case report
por: Han, Zonghong, et al.
Publicado: (2018)

Clinical features and outcome of multiple primary malignancies involving hepatocellular carcinoma: A long-term follow-up study
por: Zeng, Qing-An, et al.
Publicado: (2012)

Primary tumor location affects recurrence-free survival for patients with colorectal liver metastases after hepatectomy: a propensity score matching analysis
por: Zhang, Yuanping, et al.
Publicado: (2020)

Sorafenib Versus Apatinib Both Combined Transarterial Chemoembolization for Hepatocellular Carcinoma With Portal Vein Tumor Thrombosis: A Comparative Retrospective Study
por: Cao, Yanyan, et al.
Publicado: (2021)

Apatinib for Patients With Sorafenib-Refractory Advanced Hepatitis B Virus Related Hepatocellular Carcinoma: Results of a Pilot Study
por: Zhang, Yingqiang, et al.
Publicado: (2019)

Apatinib treatment may improve survival outcomes of patients with hepatitis B virus-related sorafenib-resistant hepatocellular carcinoma
por: Zhang, Yingqiang, et al.
Publicado: (2020)

A Combination of Sorafenib, an Immune Checkpoint Inhibitor, TACE and Stereotactic Body Radiation Therapy versus Sorafenib and TACE in Advanced Hepatocellular Carcinoma Accompanied by Portal Vein Tumor Thrombus
por: Zhang, Zeyu, et al.
Publicado: (2022)

Camrelizumab Plus Sorafenib Versus Sorafenib Monotherapy for Advanced Hepatocellular Carcinoma: A Retrospective Analysis
por: Liu, Qinqin, et al.
Publicado: (2021)

Apatinib is effective for treatment of advanced hepatocellular carcinoma
por: Kong, Yinlong, et al.
Publicado: (2017)

Apatinib as an alternative therapy for advanced hepatocellular carcinoma
por: Zhang, Xi-Hao, et al.
Publicado: (2020)

The excellent antitumor effect of apatinib alone as second-line therapy in a patient with sorafenib-refractory hepatocellular carcinoma: A case report
por: Zhu, Hong, et al.
Publicado: (2018)

Drug-Related Hypertension Associated with the Efficacy of Apatinib on Hepatocellular Carcinoma
por: Yang, XueJiao, et al.
Publicado: (2020)

Assessing the effectiveness of camrelizumab plus apatinib versus sorafenib for the treatment of primary liver cancer: a single-center retrospective study
por: Chen, Dongbo, et al.
Publicado: (2023)

Nivolumab Versus Regorafenib in Patients With Hepatocellular Carcinoma After Sorafenib Failure
por: Kuo, Yuan-Hung, et al.
Publicado: (2021)

Efficacy and Safety of Second-line Treatments in Patients with Advanced Hepatocellular Carcinoma after Sorafenib Failure: A Meta-analysis
por: An, Limin, et al.
Publicado: (2021)

Apatinib as targeted therapy for sarcoma
por: Li, Feng, et al.
Publicado: (2018)

Microwave ablation combined with apatinib and camrelizumab in patients with advanced hepatocellular carcinoma: A single-arm, preliminary study
por: Li, Xin, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_epj0jgnih5gi7cccmmd7pokvbq